The following government grants in the FederalGrants.com database contain the term housing in the listing.
Grants are sorted newest to oldest. Select a grant title to view the complete details, including information on who to contact and how to apply.
| Grant Title | CFDA | Funding Number |
| Cell-Specific Impact of Liquid-Liquid Phase Separation in Aging and AD/ADRD (R21 Clinical Trial Not Allowed) |
93.866 |
RFA-AG-23-002 |
| Cellular Senescence Network: Technology Development and Application in Murine Systems (UG3/UH3 Clinical Trial Not Allowed) |
93.310 |
RFA-RM-22-005 |
| Physiologically Based Pharmacokinetic Model for Nose-to-Brain Drug Delivery (U01) Clinical Trial Optional |
93.103 |
RFA-FD-22-016 |
| Cellular Senescence Network: Murine Tissue Mapping Centers (U54 - Clinical Trial Not Allowed) |
93.310 |
RFA-RM-22-003 |
| Elucidating the Role of Nutrition in Care and Development of Preterm Infants (R01 Clinical Trial Optional) |
93.865 |
RFA-HD-22-023 |
| Using Data Linkage to Understand Suicide Attempts, Self-Harm and Unintentional Drowning Deaths (U01) |
93.136 |
RFA-CE-22-008 |
| Rigorous Evaluation of Strategies to Prevent Overdose through Linking People with Illicit Substance Use Disorders to Recovery Support Services |
93.136 |
RFA-CE-22-010 |
| Research Grants to Evaluate the Effectiveness of Physical Therapy-based Exercises and Movements Used to Reduce Older Adults Falls (U01) |
93.136 |
RFA-CE-22-006 |
| In Vitro Approaches to Evaluate and Compare the Adhesion Performance of Transdermal and Topical Delivery Systems (TDS) (U01) Clinical Trial Required |
93.103 |
RFA-FD-22-015 |
| Understanding the Role of Bilingualism in Cognitive Reserve/Resilience in Aging and AD/ADRD (R01 Clinical Trial Optional) |
93.866 |
RFA-AG-23-001 |
| Standing Announcement for Residential (Shelter and/or Transitional Foster Care) Services for Unaccompanied Children-LICENSED AND TEXAS-EXEMPT AND FLORIDA-DELICENSED ONLY |
93.676 |
HHS-2022-ACF-ORR-ZU-0129 |
| Promoting Reproductive Health for Adolescents and Adults with Disabilities (R01 Clinical Trial Optional) |
93.313, 93.865 |
RFA-HD-23-005 |
| Research Bases for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required) |
93.393, 93.395, 93.399 |
RFA-CA-21-046 |
| Center to Support Research and Evaluation Capacity of Child Care and Development Fund Lead Agencies |
93.575 |
HHS-2022-ACF-OPRE-YE-0136 |
| Development of advanced analytical methods for the characterization of complex generics |
93.103 |
RFA-FD-22-013 |
| Investigating the in vivo behavior and in vitro characteristics purportedly gastro-retentive extended release formulation to enhance the regulatory standard of such products |
93.103 |
RFA-FD-22-018 |
| PBPK modeling to support assessment of bioequivalence of locally acting drugs in the gastrointestinal tract |
93.103 |
RFA-FD-22-012 |
| Cutaneous pharamcokinetic-based approaches to establish bioequivalence of topically applied drug products |
93.103 |
RFA-FD-22-017 |
| In Vitro Based Approaches to Evaluate the Bioequivalence of Generic Rectal and Vaginal Products |
93.103 |
RFA-FD-22-014 |
| Coordinating Center for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (U24 Clinical Trial Required) |
93.393, 93.395, 93.399 |
RFA-CA-21-045 |
| Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required) |
93.393, 93.395, 93.399 |
RFA-CA-21-047 |
| Rural eConnectivity Program |
10.752 |
RUS-REC-2022 |
| Innovative ways to provide education on antimicrobial stewardship practices in animals. |
93.103 |
PAR-22-108 |
| Research to support the development of alternatives to antimicrobials for use in food-producing animals |
93.103 |
PAR-22-087 |
| A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT; U01 Clinical Trial Optional) |
93.395 |
RFA-CA-21-063 |
| Understanding Polydrug Use Risk and Protective Factors, Patterns, and Trajectories to Prevent Drug Overdose |
93.136 |
RFA-CE-22-011 |
| Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) |
93.393 |
PAR-22-049 |
| Expanding Differentiated Care Approaches for Adolescents Living with HIV (R34 Clinical Trial Optional) |
93.242 |
RFA-MH-22-106 |
| Rigorous Evaluation of Community-Level Substance Use and Overdose Prevention Frameworks that Incorporate ACEs-Related Prevention Strategies |
93.136 |
RFA-CE-22-009 |
| Tracking the burden, distribution, and impact of Post COVID-19 conditions in diverse populations for children, adolescents, and adults (Track PCC) |
93.185 |
CDC-RFA-IP22-2203 |
| Identification and Characterization of Persistence Mechanisms of Select Protozoan Pathogens (R01 Clinical Trial Not Allowed) |
93.855 |
RFA-AI-21-075 |
| Enhanced Interpersonal Focused Strategies for Suicide Prevention Interventions (R34 Clinical Trial Required) |
93.242 |
RFA-MH-22-125 |
| Expanding Differentiated Care Approaches for Adolescents Living with HIV (R01 Clinical Trial Optional) |
93.242 |
RFA-MH-22-105 |
| NIH Blueprint for Neuroscience Research Short Courses in Neurotherapeutics Development (R25 Clinical Trial Not Allowed) |
93.113, 93.121, 93.213, 93.242, 93.273, 93.279, 93.286, 93.853, 93.865, 93.866, 93.867 |
RFA-NS-21-025 |
| Advancing Group A Streptococcus Vaccine Discovery (R01 Clinical Trial Not Allowed) |
93.855 |
RFA-AI-21-070 |
| NIH Health Care Systems Research Collaboratory - Pragmatic and Implementation Trials of Embedded Interventions (UG3/UH3, Clinical Trials Optional) |
93.213, 93.233, 93.307, 93.361, 93.837, 93.838, 93.839, 93.840, 93.846, 93.866 |
RFA-AT-22-001 |
| Diabetes Research Centers (P30 Clinical Trial Optional) |
93.847 |
RFA-DK-21-029 |
| Pelvic Floor Disorders Network (UG1 Clinical Trial Required) |
93.313, 93.865 |
RFA-HD-22-021 |
| Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed) |
93.242 |
PAR-22-038 |
| Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) |
93.393, 93.399 |
PAR-21-341 |
Search Results 3041-3080 of 17940
[Prev] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 [Next] |
